Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TENX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTenax Therapeutics reports Q1 2026 financial results
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing first quarter 2026 financial results for period ended March 31, 2026. Specific financial metrics not disclosed in 8-K filing body.
Item 2.02 verify on EDGAR → -
medium
Full financial details contained in attached press release exhibit (Exhibit 99.1), which is referenced but not summarized in the filing.
8-K: Exhibit 99.1 view on EDGAR →
Summary
Tenax Therapeutics filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 12, 2026. This is a routine quarterly earnings disclosure required under Item 2.02 of Form 8-K. The filing itself contains minimal detail, with the actual financial metrics and management commentary contained in the attached press release exhibit.
Retail investors should review the full press release (Exhibit 99.1) to understand the company's Q1 performance, including revenue, expenses, cash position, and any updates on clinical programs or business strategy. As a clinical-stage biopharmaceutical company, key metrics to watch include cash runway, clinical trial progress, and any regulatory milestones. The next quarterly update will provide insight into whether the company is maintaining its development timeline and financial stability.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Tenax Therapeutics announced Q1 2026 financial results via press release on May 12, 2026.
Added in current filing · verify on EDGAR →
On May 12, 2026, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The actual financial details are contained in the attached press release exhibit, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Tenax Therapeutics filed an 8-K attaching a press release dated May 12, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press release dated May 12, 2026.
The 8-K references an attached press release dated May 12, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content or the underlying corporate event. Without access to the exhibit, the materiality and nature of the announcement cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify